Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial

EP Europace Journal

24 September 2025
Organised by: Logo
ESC Journals ARRHYTHMIAS AND DEVICE THERAPY HEART FAILURE Chronic Heart Failure Atrial Fibrillation (AF) Device Therapy

Abstract

AbstractAims

Atrial fibrillation (AF) is associated with an increased risk of sudden cardiac death. Therefore, the effect of an implantable cardioverter-defibrillator (ICD) may be greater in patients with AF. We examined the long-term effects of primary prevention ICD implantation vs. usual clinical care according to AF status in DANISH.

Methods and results

Outcomes were analysed according to AF status at baseline (history and/or on enrollment ECG). The primary outcome was all-cause death, and secondary outcomes were cardiovascular and sudden cardiovascular death. Of the 1116 patients with non-ischaemic heart failure with reduced ejection fraction randomized in DANISH, 418 (37.5%) had AF at baseline, of whom 24.2% had paroxysmal AF, 17.0% persistent AF, and 58.9% permanent AF. AF status did not significantly modify the effect of ICD implantation on all-cause death, although there was a suggestion of a greater effect in patients with [hazard ratio (HR) 0.78 (95% CI, 0.59–1.03)] vs. without AF [HR 0.98 (0.75–1.27)] (Pinteraction = 0.15). AF status significantly modified the effect of ICD implantation on cardiovascular death, such that ICD implantation was associated with a lower rate of this outcome in patients with AF [HR 0.67 (0.48–0.94)], but not in those without AF [HR 1.04 (0.76–1.41)] (Pinteraction = 0.04). Although AF status did not significantly modify the effect of ICD implantation on sudden cardiovascular death, there was a suggestion of a greater effect in patients with [HR 0.45 (0.24–0.82)] vs. without AF [HR 0.76 (0.41–1.38)] (Pinteraction = 0.20).

Conclusion

In the DANISH trial, the presence of AF was associated with a greater effect of ICD implantation on cardiovascular death, and although similar trends were observed for all-cause and sudden cardiovascular death, the treatment-by-subgroup interaction was not statistically significant for these outcomes.

Registration

URL: https://www.clinicaltrials.gov; unique identifier: NCT00542945.

Contributors

Adelina Yafasova
Adelina Yafasova

Author

Rigshospitalet - Copenhagen University Hospital Copenhagen , Denmark

Jens Jakob Thune
Jens Jakob Thune

Author

Copenhagen University Hospital - Bispebjerg and Frederiksberg Copenhagen , Denmark

Christian Hassager
Christian Hassager

Author

Rigshospitalet - Copenhagen University Hospital Copenhagen , Denmark

Jesper H Svendsen
Jesper H Svendsen

Author

Rigshospitalet - Copenhagen University Hospital Copenhagen , Denmark

Dan E Høfsten
Dan E Høfsten

Author

Rigshospitalet - Copenhagen University Hospital Copenhagen , Denmark

Lars Køber
Lars Køber

Author

Rigshospitalet - Copenhagen University Hospital Copenhagen , Denmark

Jawad H Butt
Jawad H Butt

Author

Rigshospitalet - Copenhagen University Hospital Copenhagen , Denmark

ESC 365 is supported by